Publications

Found 1 results
Filters: Author is L.R. Zhao  [Clear All Filters]
2012
L. P. Wang, Zhao, L. R., Cui, H. W., Yan, M. R., Yang, L., and Su, X. L., Association between PPARγ2 Pro12Ala polymorphism and myocardial infarction and obesity in Han Chinese in Hohhot, China, vol. 11, pp. 2929-2938, 2012.
Akiyama TE, Sakai S, Lambert G, Nicol CJ, et al. (2002). Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell Biol. 22: 2607-2619. http://dx.doi.org/10.1128/MCB.22.8.2607-2619.2002 PMid:11909955 PMCid:133709   Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, et al. (2000). The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26: 76-80. http://dx.doi.org/10.1038/79216 PMid:10973253   Beamer BA, Yen CJ, Andersen RE, Muller D, et al. (1998). Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47: 1806-1808. http://dx.doi.org/10.2337/diabetes.47.11.1806 PMid:9792554   Black MH, Fingerlin TE, Allayee H, Zhang W, et al. (2008). Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes 57: 1048-1056. http://dx.doi.org/10.2337/db07-0848 PMid:18162503   Bouhlel MA, Derudas B, Rigamonti E, Dievart R, et al. (2007). PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6: 137-143. http://dx.doi.org/10.1016/j.cmet.2007.06.010 PMid:17681149   Danawati CW, Nagata M, Moriyama H, Hara K, et al. (2005). A possible association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 gene with obesity in native Javanese in Indonesia. Diabetes Metab. Res. Rev. 21: 465-469. http://dx.doi.org/10.1002/dmrr.543 PMid:15739197   Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, et al. (1998). A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20: 284-287. http://dx.doi.org/10.1038/3099 PMid:9806549   Ghoussaini M, Meyre D, Lobbens S, Charpentier G, et al. (2005). Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med. Genet. 6: 11. http://dx.doi.org/10.1186/1471-2350-6-11 PMid:15784141 PMCid:1084346   Holvoet P (2008). Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd. Belg. 70: 193-219. PMid:18669160   Hsueh WA and Bruemmer D (2004). Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 43: 297-305. http://dx.doi.org/10.1161/01.HYP.0000113626.76571.5b PMid:14732733   Hu Q, Zhang XJ, Liu CX, Wang XP, et al. (2010). PPARgamma1-induced caveolin-1 enhances cholesterol efflux and attenuates atherosclerosis in apolipoprotein E-deficient mice. J. Vasc. Res. 47: 69-79. http://dx.doi.org/10.1159/000235927 PMid:19729954   Issemann I and Green S (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650. http://dx.doi.org/10.1038/347645a0 PMid:2129546   Iwai M, Kanno H, Senba I, Nakaoka H, et al. (2011). Irbesartan increased PPARgamma activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem. Biophys. Res. Commun. 406: 123-126. http://dx.doi.org/10.1016/j.bbrc.2011.02.007 PMid:21296052   Ji Y, Liu J, Wang Z, Liu N, et al. (2009). PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab. Invest. 89: 887-902. http://dx.doi.org/10.1038/labinvest.2009.45 PMid:19451898   Kagawa Y, Yanagisawa Y, Hasegawa K, Suzuki H, et al. (2002). Single nucleotide polymorphisms of thrifty genes for energy metabolism: evolutionary origins and prospects for intervention to prevent obesity-related diseases. Biochem. Biophys. Res. Commun. 295: 207-222. http://dx.doi.org/10.1016/S0006-291X(02)00680-0   Kim KS, Choi SM, Shin SU, Yang HS, et al. (2004). Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism 53: 1538-1543. http://dx.doi.org/10.1016/j.metabol.2004.06.019 PMid:15562396   Kolehmainen M, Uusitupa MI, Alhava E, Laakso M, et al. (2003). Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. J. Clin. Endocrinol. Metab. 88: 1717-1722. http://dx.doi.org/10.1210/jc.2002-020603 PMid:12679463   Liu L, Liu L, Ding Y, Huang Z, et al. (2001). Ethnic and environmental differences in various markers of dietary intake and blood pressure among Chinese Han and three other minority peoples of China: results from the WHO Cardiovascular Diseases and Alimentary Comparison (CARDIAC) Study. Hypertens. Res. 24: 315-322. http://dx.doi.org/10.1291/hypres.24.315 PMid:11409657   Masud S and Ye S (2003). Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J. Med. Genet. 40: 773-780. http://dx.doi.org/10.1136/jmg.40.10.773 PMid:14569127 PMCid:1735275   McDermott MM (2007). The international pandemic of chronic cardiovascular disease. JAMA 297: 1253-1255. http://dx.doi.org/10.1001/jama.297.11.1253 PMid:17374819   Meirhaeghe A, Fajas L, Helbecque N, Cottel D, et al. (2000). Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 24: 195-199. http://dx.doi.org/10.1038/sj.ijo.0801112 PMid:10702770   Miyazaki Y, Mahankali A, Matsuda M, Glass L, et al. (2001). Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-719. http://dx.doi.org/10.2337/diacare.24.4.710 PMid:11315836   Moran CS, Cullen B, Campbell JH and Golledge J (2009). Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J. Vasc. Res. 46: 209-217. http://dx.doi.org/10.1159/000163019 PMid:18931513   Mori H, Ikegami H, Kawaguchi Y, Seino S, et al. (2001). The Pro12 →Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50: 891-894. http://dx.doi.org/10.2337/diabetes.50.4.891 PMid:11289058   Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, et al. (1998). Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem. Biophys. Res. Commun. 251: 195-198. http://dx.doi.org/10.1006/bbrc.1998.9421 PMid:9790929   Pan XF, Song XB, Wang LL, Li LX, et al. (2009). Association of the Pro12Ala polymorphism in peroxisome proliferators activated receptor-gamma gene with rheumatoid arthritis in Sichuan Province of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26: 87-90. PMid:19199260   Ren Y, Sun C, Sun Y, Tan H, et al. (2009). PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul. Pharmacol. 51: 169-174. http://dx.doi.org/10.1016/j.vph.2009.06.004 PMid:19540934   Ridker PM, Cook NR, Cheng S, Erlich HA, et al. (2003). Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23: 859-863. http://dx.doi.org/10.1161/01.ATV.0000068680.19521.34 PMid:12663371   Rose GA and Blackburn H (1982). Cardiovascular Survey Methods. World Health Organization. WHO Monograph Series, Geneva.   Schaffler A, Barth N, Schmitz G, Zietz B, et al. (2001). Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine. 14: 369-373. http://dx.doi.org/10.1385/ENDO:14:3:369   Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, et al. (2006). Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch. Med. Res. 37: 736-743. http://dx.doi.org/10.1016/j.arcmed.2006.01.009 PMid:16824933   Tamori Y, Masugi J, Nishino N and Kasuga M (2002). Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51: 2045-2055. http://dx.doi.org/10.2337/diabetes.51.7.2045 PMid:12086932   Tavares V, Hirata RD, Rodrigues AC, Monte O, et al. (2005). Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes. Metab. 7: 605-611. http://dx.doi.org/10.1111/j.1463-1326.2004.00453.x PMid:16050954   Wang G, Wei J, Guan Y, Jin N, et al. (2005). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 54: 590-597. http://dx.doi.org/10.1016/j.metabol.2004.11.017 PMid:15877288   Wei Q, Jacobs DR, Jr., Schreiner PJ, Siscovick DS, et al. (2006). Patterns of association between PPARgamma genetic variation and indices of adiposity and insulin action in African-Americans and whites: the CARDIA Study. J. Mol. Med. 84: 955-965. http://dx.doi.org/10.1007/s00109-006-0088-7 PMid:16955276   Yamamoto Y, Hirose H, Miyashita K, Nishikai K, et al. (2002). PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism 51: 1407- 1409. http://dx.doi.org/10.1053/meta.2002.35586 PMid:12404189   Yen CJ, Beamer BA, Negri C, Silver K, et al. (1997). Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 241: 270-274. http://dx.doi.org/10.1006/bbrc.1997.7798 PMid:9425261   Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, et al. (2008). Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc. Health Risk Manag. 4: 427-436. PMid:18561518 PMCid:2496990